While administration of TNFα of IFNγ may or may not be tolerable clinically, selective enhancement of NFκB and MUC16 levels in cancer cells by other methods might provide a provocative test to confirm the presence of early stage ovarian cancer in asymptomatic women with rising levels of serum CA125 (MUC16). This evidence concerns the gene NFKB1 and ovarian cancer.